MA39450B2 - Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine - Google Patents

Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Info

Publication number
MA39450B2
MA39450B2 MA39450A MA39450A MA39450B2 MA 39450 B2 MA39450 B2 MA 39450B2 MA 39450 A MA39450 A MA 39450A MA 39450 A MA39450 A MA 39450A MA 39450 B2 MA39450 B2 MA 39450B2
Authority
MA
Morocco
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
enantiomers
medicine
Prior art date
Application number
MA39450A
Other languages
English (en)
Other versions
MA39450A1 (fr
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Ramos Damil
Oliveira Santos Pedro Paulo De Lacerda E
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA39450A1 publication Critical patent/MA39450A1/fr
Publication of MA39450B2 publication Critical patent/MA39450B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des sels pharmaceutiquement acceptables de composés de (r)-pirlindole et de (s)-pirlindole énantiomériquement purs, qui présentent un profil de biodisponibilité acrrue et se destinent à un usage médical.
MA39450A 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine MA39450B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Publications (2)

Publication Number Publication Date
MA39450A1 MA39450A1 (fr) 2017-08-31
MA39450B2 true MA39450B2 (fr) 2021-10-29

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39450A MA39450B2 (fr) 2014-05-09 2014-05-09 Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine

Country Status (22)

Country Link
US (1) US10226460B2 (fr)
EP (2) EP3139926A1 (fr)
JP (1) JP6400121B2 (fr)
KR (1) KR102276281B1 (fr)
CN (1) CN106413713B (fr)
AU (1) AU2014393487B2 (fr)
CA (1) CA2948595C (fr)
DK (1) DK3831385T3 (fr)
EC (1) ECSP16086196A (fr)
FI (1) FI3831385T3 (fr)
IL (1) IL248852B (fr)
LT (1) LT3831385T (fr)
MA (1) MA39450B2 (fr)
MX (1) MX2016014704A (fr)
NZ (1) NZ726127A (fr)
PH (1) PH12016502235A1 (fr)
PT (1) PT3831385T (fr)
RU (1) RU2706688C2 (fr)
SA (1) SA516380258B1 (fr)
TN (1) TN2016000495A1 (fr)
UA (1) UA118587C2 (fr)
WO (1) WO2015171002A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3057589T3 (pl) * 2014-05-09 2018-01-31 Tecnimede Sociedade Tecnico Medicinal S (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie
CA2948596C (fr) * 2014-05-09 2021-06-08 Tecnimede Sociedade Tecnico-Medicinal S.A. (r)-pirlindole et ses sels pharmaceutiquement acceptables destines a un usage medical
EP3392250A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
EP3392251A1 (fr) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170473B1 (da) * 1985-06-20 1995-09-11 Daiichi Seiyaku Co S(-)-pyridobenzoxazinforbindelser
CA2500662A1 (fr) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
EP1688161A1 (fr) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
US20150250808A1 (en) * 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
PL3057589T3 (pl) * 2014-05-09 2018-01-31 Tecnimede Sociedade Tecnico Medicinal S (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie
CA2948596C (fr) * 2014-05-09 2021-06-08 Tecnimede Sociedade Tecnico-Medicinal S.A. (r)-pirlindole et ses sels pharmaceutiquement acceptables destines a un usage medical
DK3140265T3 (da) * 2014-05-09 2019-11-18 Tecnimede Sociedade Tecnico Medicinal S Fremgangsmåde til at opnå optisk aktive pirlindolenantiomerer og salte deraf

Also Published As

Publication number Publication date
PT3831385T (pt) 2024-09-24
US10226460B2 (en) 2019-03-12
AU2014393487B2 (en) 2020-01-02
FI3831385T3 (fi) 2024-09-04
EP3139926A1 (fr) 2017-03-15
KR20170002433A (ko) 2017-01-06
KR102276281B1 (ko) 2021-07-13
RU2016148174A (ru) 2018-06-14
NZ726127A (en) 2019-03-29
TN2016000495A1 (en) 2018-04-04
CA2948595C (fr) 2021-07-13
ECSP16086196A (es) 2017-02-24
WO2015171002A1 (fr) 2015-11-12
SA516380258B1 (ar) 2019-11-04
MX2016014704A (es) 2017-05-23
RU2706688C2 (ru) 2019-11-20
LT3831385T (lt) 2024-09-10
AU2014393487A1 (en) 2016-11-24
EP3831385B1 (fr) 2024-07-10
IL248852B (en) 2020-05-31
JP6400121B2 (ja) 2018-10-03
PH12016502235A1 (en) 2017-01-09
EP3831385A1 (fr) 2021-06-09
US20170143710A1 (en) 2017-05-25
CN106413713B (zh) 2020-07-14
UA118587C2 (uk) 2019-02-11
DK3831385T3 (da) 2024-08-26
IL248852A0 (en) 2017-01-31
MA39450A1 (fr) 2017-08-31
RU2016148174A3 (fr) 2018-06-14
CA2948595A1 (fr) 2015-11-12
CN106413713A (zh) 2017-02-15
JP2017514882A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
CO2018011064A2 (es) Inhibidores de bromodominios
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
EP3970712A3 (fr) Formes posologiques solides orales de 2r, 6r-hydroxynorkétamine ou leurs dérivés
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX2017016802A (es) Formulaciones farmaceuticas.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
SV2016005313A (es) Derivados de carboxamida
EP3405211A4 (fr) Octréotide par voie orale pour le traitement de maladies
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MA39450B2 (fr) Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
GB2501050A (en) Pharmaceutical compositons of immunosuppressants
EA201991141A1 (ru) Усилители bmp
TH1601007484A (th) สารประกอบเฮเทอโรแอริลสำหรับการยับยั้งไคเนส